Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):418–424. doi: 10.1038/bjc.1993.352

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

J Prendiville 1, D Crowther 1, N Thatcher 1, P J Woll 1, B W Fox 1, A McGown 1, N Testa 1, P Stern 1, R McDermott 1, M Potter 1, et al.
PMCID: PMC1968558  PMID: 8347500

Abstract

Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum Ectoprocta. Nineteen patients with advanced solid tumours were entered into a phase I study to evaluate the toxicity and biological effects of bryostatin 1. Bryostatin 1 was given as a one hour intravenous infusion at the beginning of each 2 week treatment cycle. A maximum of three treatment cycles were given. Doses were escalated in steps from 5 to 65 micrograms m-2 in successive patient groups. The maximum tolerated dose was 50 micrograms m-2. Myalgia was the dose limiting toxicity and was of WHO grade 3 in all three patients treated at 65 micrograms m-2. Flu-like symptoms were common but were of maximum WHO grade 2. Hypotension, of maximum WHO grade 1, occurred in six patients treated at doses up to and including 20 micrograms m-2 and may not have been attributable to treatment with bryostatin 1. Cellulitis and thrombophlebitis occurred at the bryostatin 1 infusion site of patients treated at all dose levels up to 50 micrograms m-2, attributable to the 60% ethanol diluent in the bryostatin 1 infusion. Subsequent patients treated at 50 and 65 micrograms m-2 received treatment with an intravenous normal saline flush and they did not develop these complications. Significant decreases of the platelet count and total leucocyte, neutrophil and lymphocyte counts were seen in the first 24 h after treatment at the dose of 65 micrograms m-2. Immediate decreases in haemoglobin of up to 1.9g dl-1 were also noted in patients treated with 65 micrograms m-2, in the absence of clinical evidence of bleeding or haemodynamic compromise. No effect was observed on the incidence of haemopoietic progenitor cells in the marrow. Some patients' neutrophils demonstrated enhanced superoxide radical formation in response to in vitro stimulation with opsonised zymosan (a bacterial polysaccharide) but in the absence of this additional stimulus, no bryostatin 1 effect was observed. Lymphocyte natural killing activity was decreased 2 h after treatment with bryostatin 1, but the effect was not consistently seen 24 h or 7 days later. With the dose schedule examined no antitumour effects were observed. We recommend that bryostatin 1 is used at a dose of 35 to 50 micrograms m-2 two weekly in phase II studies in patients with malignancies including lymphoma, leukaemia, melanoma or hypernephroma, for which pre-clinical investigations suggest antitumour activity.

Full text

PDF
418

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berkow R. L., Kraft A. S. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun. 1985 Sep 30;131(3):1109–1116. doi: 10.1016/0006-291x(85)90205-0. [DOI] [PubMed] [Google Scholar]
  2. Brinkmeier H., Jockusch H. Activators of protein kinase C induce myotonia by lowering chloride conductance in muscle. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1383–1389. doi: 10.1016/s0006-291x(87)80285-1. [DOI] [PubMed] [Google Scholar]
  3. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982 Jul 10;257(13):7847–7851. [PubMed] [Google Scholar]
  4. Dale I. L., Gescher A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer. 1989 Jan 15;43(1):158–163. doi: 10.1002/ijc.2910430129. [DOI] [PubMed] [Google Scholar]
  5. Drexler H. G., Gignac S. M., Pettit G. R., Hoffbrand A. V. Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation. Eur J Immunol. 1990 Jan;20(1):119–127. doi: 10.1002/eji.1830200118. [DOI] [PubMed] [Google Scholar]
  6. Easmon C. S., Cole P. J., Williams A. J., Hastings M. The measurement of opsonic and phagocytic function by Luminol-dependent chemiluminescence. Immunology. 1980 Sep;41(1):67–74. [PMC free article] [PubMed] [Google Scholar]
  7. Fields A. P., Pettit G. R., May W. S. Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C. J Biol Chem. 1988 Jun 15;263(17):8253–8260. [PubMed] [Google Scholar]
  8. Gebbia V., Di Marco P., Miceli S., Reyes M. B., Teresi M., Bonaccorso R., Citarrella P., Rausa L. The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells. Haematologica. 1988 Sep-Oct;73(5):387–391. [PubMed] [Google Scholar]
  9. Ghosh A. K., Dazzi H., Thatcher N., Moore M. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer. 1989 Mar 15;43(3):410–414. doi: 10.1002/ijc.2910430311. [DOI] [PubMed] [Google Scholar]
  10. Hennings H., Blumberg P. M., Pettit G. R., Herald C. L., Shores R., Yuspa S. H. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis. 1987 Sep;8(9):1343–1346. doi: 10.1093/carcin/8.9.1343. [DOI] [PubMed] [Google Scholar]
  11. Hess A. D., Silanskis M. K., Esa A. H., Pettit G. R., May W. S. Activation of human T lymphocytes by bryostatin. J Immunol. 1988 Nov 15;141(10):3263–3269. [PubMed] [Google Scholar]
  12. Hornung R. L., Pearson J. W., Beckwith M., Longo D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 1992 Jan 1;52(1):101–107. [PubMed] [Google Scholar]
  13. Jalava A. M., Heikkilä J., Akerlind G., Pettit G. R., Akerman K. E. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Cancer Res. 1990 Jun 1;50(11):3422–3428. [PubMed] [Google Scholar]
  14. Jetten A. M., George M. A., Pettit G. R., Rearick J. I. Effects of bryostatins and retinoic acid on phorbol ester- and diacylglycerol-induced squamous differentiation in human tracheobronchial epithelial cells. Cancer Res. 1989 Jul 15;49(14):3990–3995. [PubMed] [Google Scholar]
  15. Jones R. A., Drexler H. G., Gignac S. M., Child J. A., Scott C. S. In vitro beta 2-microglobulin (beta 2m) secretion by normal and leukaemic B-cells: effects of recombinant cytokines and evidence for a differential response to the combined stimulus of phorbol ester and calcium ionophore. Br J Cancer. 1990 May;61(5):675–680. doi: 10.1038/bjc.1990.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kiss Z., Deli E., Girard P. R., Pettit G. R., Kuo J. F. Comparative effects of polymyxin B, phorbol ester and bryostatin on protein phosphorylation, protein kinase C translocation, phospholipid metabolism and differentiation of HL60 cells. Biochem Biophys Res Commun. 1987 Jul 15;146(1):208–215. doi: 10.1016/0006-291x(87)90712-1. [DOI] [PubMed] [Google Scholar]
  17. Kiss Z., Deli E., Shoji M., Koeffler H. P., Pettit G. R., Vogler W. R., Kuo J. F. Differential effects of various protein kinase C activators on protein phosphorylation in human acute myeloblastic leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a. Cancer Res. 1987 Mar 1;47(5):1302–1307. [PubMed] [Google Scholar]
  18. Kraft A. S., William F., Pettit G. R., Lilly M. B. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 1;49(5):1287–1293. [PubMed] [Google Scholar]
  19. Leonard J. P., May W. S., Ihle J. N., Pettit G. R., Sharkis S. J. Regulation of hematopoiesis-IV: The role of interleukin-3 and bryostatin 1 in the growth of erythropoietic progenitors from normal and anemic W/Wv mice. Blood. 1988 Nov;72(5):1492–1496. [PubMed] [Google Scholar]
  20. Lilly M., Brown C., Pettit G., Kraft A. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr;5(4):283–287. [PubMed] [Google Scholar]
  21. Lilly M., Tompkins C., Brown C., Pettit G., Kraft A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 1;50(17):5520–5525. [PubMed] [Google Scholar]
  22. May W. S., Sharkis S. J., Esa A. H., Gebbia V., Kraft A. S., Pettit G. R., Sensenbrenner L. L. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8483–8487. doi: 10.1073/pnas.84.23.8483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McCrady C. W., Staniswalis J., Pettit G. R., Howe C., Grant S. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. Br J Haematol. 1991 Jan;77(1):5–15. doi: 10.1111/j.1365-2141.1991.tb07941.x. [DOI] [PubMed] [Google Scholar]
  24. Sako T., Yuspa S. H., Herald C. L., Pettit G. R., Blumberg P. M. Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells. Cancer Res. 1987 Oct 15;47(20):5445–5450. [PubMed] [Google Scholar]
  25. Schuchter L. M., Esa A. H., May S., Laulis M. K., Pettit G. R., Hess A. D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res. 1991 Jan 15;51(2):682–687. [PubMed] [Google Scholar]
  26. Sharkis S. J., Jones R. J., Bellis M. L., Demetri G. D., Griffin J. D., Civin C., May W. S. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15;76(4):716–720. [PubMed] [Google Scholar]
  27. Stone R. M., Sariban E., Pettit G. R., Kufe D. W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Jul;72(1):208–213. [PubMed] [Google Scholar]
  28. Tallant E. A., Smith J. B., Wallace R. W. Bryostatins mimic the effects of phorbol esters in intact human platelets. Biochim Biophys Acta. 1987 Jun 15;929(1):40–46. doi: 10.1016/0167-4889(87)90239-4. [DOI] [PubMed] [Google Scholar]
  29. Tilden A. B., Kraft A. S. The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity. J Immunother (1991) 1991 Apr;10(2):96–104. doi: 10.1097/00002371-199104000-00003. [DOI] [PubMed] [Google Scholar]
  30. Trenn G., Pettit G. R., Takayama H., Hu-Li J., Sitkovsky M. V. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J Immunol. 1988 Jan 15;140(2):433–439. [PubMed] [Google Scholar]
  31. Warren B. S., Kamano Y., Pettit G. R., Blumberg P. M. Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations. Cancer Res. 1988 Nov 1;48(21):5984–5988. [PubMed] [Google Scholar]
  32. William F., Mroczkowski B., Cohen S., Kraft A. S. Differentiation of HL-60 cells is associated with an increase in the 35-kDa protein lipocortin I. J Cell Physiol. 1988 Dec;137(3):402–410. doi: 10.1002/jcp.1041370303. [DOI] [PubMed] [Google Scholar]
  33. al-Katib A., Mohammad R. M., Mohamed A. N., Pettit G. R., Sensenbrenner L. L. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol Oncol. 1990 Mar-Apr;8(2):81–89. doi: 10.1002/hon.2900080203. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES